Glaukos (GKOS) Expected to Announce Earnings on Tuesday

Glaukos (NYSE:GKOS) is expected to be announcing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $132.1570 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

Glaukos Price Performance

NYSE:GKOS opened at $113.26 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. The company has a 50-day moving average of $114.49 and a 200-day moving average of $97.60. Glaukos has a 52 week low of $73.16 and a 52 week high of $161.78. The company has a market capitalization of $6.51 billion, a price-to-earnings ratio of -73.55 and a beta of 0.70.

Insider Activity

In other Glaukos news, CEO Thomas William Burns sold 186,945 shares of Glaukos stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares in the company, valued at approximately $17,684,125. The trade was a 54.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 10,498 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total value of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at $11,793,290.88. The trade was a 10.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 329,655 shares of company stock worth $37,752,234. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Glaukos

A number of hedge funds have recently added to or reduced their stakes in GKOS. Wellington Management Group LLP increased its position in Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after acquiring an additional 336,266 shares in the last quarter. State Street Corp lifted its position in shares of Glaukos by 5.3% during the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after purchasing an additional 105,972 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after purchasing an additional 68,497 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Glaukos by 66.3% in the third quarter. Bank of America Corp DE now owns 474,930 shares of the medical instruments supplier’s stock valued at $38,731,000 after purchasing an additional 189,284 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its position in Glaukos by 87.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 367,528 shares of the medical instruments supplier’s stock worth $29,972,000 after purchasing an additional 171,163 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on GKOS. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Stephens increased their target price on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 2nd. BTIG Research boosted their price target on Glaukos from $123.00 to $131.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Stifel Nicolaus upped their price target on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Citigroup lifted their price objective on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $132.54.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.